Paraquat Lawsuit Settlements: What Parkinson's Victims Can Expect (2025)

For decades, farm workers, pesticide applicators, and agricultural laborers across the United States handled a herbicide called paraquat without being told it was linked to a devastating, incurable neurological disease. Today, more than 5,000 plaintiffs have filed lawsuits alleging that their Parkinson's disease was caused by paraquat exposure — and the litigation is building toward what legal analysts are projecting could be a $3 to $6 billion total settlement. If you or a family member developed Parkinson's disease after working with or around paraquat, this guide explains how the litigation works, what individual cases are projected to be worth, and what evidence you need to file a claim.

What Is Paraquat? Gramoxone, Chevron, and Syngenta

Paraquat dichloride is a broad-spectrum contact herbicide that kills virtually any green plant it touches. It has been sold in the United States since the early 1960s under brand names including Gramoxone, Ortho Paraquat CL, Blanco, and Cyclone. Paraquat is valued in industrial agriculture because it works extremely fast, kills weeds on contact within hours, and has no soil residual activity — meaning a field can be replanted quickly after application.

The commercial history of paraquat in the US involves two major corporate players who feature prominently in the lawsuits. Chevron Chemical Company (now Chevron Phillips Chemical) was the primary US distributor of Gramoxone from the 1960s through the 1980s and continued marketing the product for decades. Syngenta AG, the Swiss-headquartered agrochemical giant, is the current global manufacturer and the principal defendant in the ongoing litigation. Both companies are accused of knowing for years that paraquat posed serious neurological risks — including a link to Parkinson's disease — and failing to adequately warn users.

Paraquat is extraordinarily toxic. A single sip — less than a teaspoon — of concentrated paraquat solution can be fatal to an adult with no antidote available. Even non-lethal exposures through skin contact, inhalation of spray drift, or ingestion of residue have been associated with long-term organ damage. The chemical is so dangerous that the US Environmental Protection Agency classifies it as a Restricted Use Pesticide, meaning it can only be purchased and applied by licensed commercial applicators. The general public cannot legally buy it.

The Parkinson's Disease Link: What the Science Shows

The scientific evidence linking paraquat to Parkinson's disease is extensive and has been building for more than two decades. Parkinson's disease is a progressive neurodegenerative disorder caused by the death of dopamine-producing neurons in a region of the brain called the substantia nigra. The motor symptoms — tremors, rigidity, slowed movement, balance problems — are caused by dopamine depletion, and there is no cure. The disease is typically managed with medications that supplement or mimic dopamine, but it progresses over time regardless of treatment.

The key scientific milestone in the paraquat litigation came from the National Institute of Environmental Health Sciences (NIEHS). A landmark 2011 study published in the peer-reviewed journal Environmental Health Perspectives found that people exposed to paraquat were approximately 150% more likely to develop Parkinson's disease than unexposed individuals — a 2.5-fold increase in risk. The study analyzed data from the Agricultural Health Study, a long-running cohort of licensed pesticide applicators and their spouses in Iowa and North Carolina.

The biological mechanism is well-understood and provides crucial support for the legal causation argument. Paraquat is structurally similar to a well-known neurotoxin called MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which was discovered to cause Parkinson's-like symptoms in humans in the 1980s. Both paraquat and MPTP appear to damage neurons by generating reactive oxygen species — a form of cellular oxidative stress — in the substantia nigra. Animal studies dating back to the 1990s have reproducibly induced Parkinson's-like neurodegeneration in rodents by exposing them to paraquat. The NIEHS-funded Farming and Movement Evaluation (FAME) study further found that paraquat use within 1,600 feet of a residential address was associated with elevated Parkinson's risk in surrounding populations.

The EPA's own 2019 preliminary risk assessment acknowledged the neurotoxic potential of paraquat while stopping short of the regulatory action that many scientists and advocates have called for. The International Parkinson and Movement Disorder Society has listed paraquat as an environmental risk factor for Parkinson's disease in its scientific consensus statements. In short, the scientific community has reached substantial consensus on the link — the question in litigation is not whether the link exists but how individual plaintiffs can prove their specific exposure caused their specific diagnosis.

MDL No. 3004: The Southern District of Illinois Litigation

The paraquat Parkinson's lawsuits are consolidated in a federal multidistrict litigation (MDL) designated MDL No. 3004, pending before U.S. District Judge Nancy J. Rosenstengel in the Southern District of Illinois in East St. Louis. The MDL was created in June 2021 to coordinate the pretrial proceedings for all federally filed paraquat Parkinson's cases, avoiding duplicative discovery and inconsistent rulings on common legal questions.

By late 2024, the MDL contained more than 5,000 individual cases, and new cases continue to be filed as awareness of the litigation spreads through farm worker communities and legal advertising channels. The principal defendants are Syngenta Crop Protection, LLC and its affiliates, along with Chevron USA Inc. Both defendants have denied liability, arguing that the scientific evidence does not establish causation for individual plaintiffs and that their warning labels were adequate under federal law.

One of the most consequential early battles in the MDL was a Daubert hearing — a process by which the court evaluates whether expert witnesses are qualified and whether their opinions are based on sufficiently reliable methodology. In 2023, Judge Rosenstengel issued a ruling on the plaintiffs' general causation experts, which is the threshold question of whether paraquat can, at a biological level, cause Parkinson's disease in humans. The court's handling of general causation has significant implications for the viability of the entire MDL and has been closely watched by attorneys on both sides.

The MDL process typically moves through discovery, general causation expert battles, a small number of bellwether trials (test cases selected to give both sides a realistic picture of how juries evaluate the claims), and then settlement negotiations that are informed by those verdicts. The paraquat MDL is proceeding through this standard playbook, with bellwether trials expected to provide critical data on case values in 2025.

Bellwether Trial Schedule 2025

Bellwether trials in the paraquat MDL are scheduled to begin in 2025. These trials are not class action settlements — each bellwether case involves an individual plaintiff whose specific exposure history, diagnosis, and damages are presented to a jury. The verdicts do not bind other plaintiffs, but they serve as powerful data points that drive settlement negotiations.

In comparable mass tort litigations, bellwether trials have been the decisive event that unlocked global settlements. In the Roundup glyphosate MDL, three early bellwether-style trials in California state court produced verdicts of $78.5 million, $80 million, and $2 billion (later reduced on appeal), which directly precipitated Bayer/Monsanto's announcement of a $10.9 billion global settlement in 2020. Legal analysts watching the paraquat MDL expect a similar dynamic: if bellwether juries return substantial verdicts in favor of Parkinson's disease plaintiffs, settlement discussions with Syngenta and Chevron will accelerate rapidly.

The 2025 bellwether schedule is expected to focus on plaintiffs with well-documented occupational exposure — licensed applicators or farm employees with pesticide application logs, employment records, and confirmed Parkinson's diagnoses from neurologists. These clean fact patterns are selected by attorneys on both sides specifically because they give the clearest possible signal about how juries will evaluate the core causation and damages questions.

Projected Settlement Range: $3 to $6 Billion Total

No global paraquat settlement has been announced as of mid-2025. The projections discussed below are based on analysis of the MDL's case count, the strength of the scientific evidence, comparable MDL outcomes, and information published by plaintiffs' attorneys who specialize in mass tort litigation. They should be understood as informed estimates, not guarantees.

The most commonly cited benchmark is the Roundup glyphosate litigation. At the time of Bayer's 2020 settlement, the MDL and related state court dockets contained approximately 125,000 to 160,000 cases. The $10.9 billion settlement worked out to roughly $68,000 to $87,000 per case on average, though actual individual payments varied widely based on cancer type, severity, and exposure duration. Importantly, the vast majority of Roundup cases involved Non-Hodgkin's lymphoma, which is a serious but often treatable and sometimes curable cancer. Parkinson's disease, by contrast, is an incurable, permanently progressive neurological condition that typically causes severe disability over many years — a fact that supports higher individual valuations.

Given the paraquat MDL's current scale of roughly 5,000-plus cases (compared to Roundup's 125,000+), even a modest per-case average of $600,000 to $1.2 million would produce a total settlement in the $3 to $6 billion range. Legal analysts and mass tort attorneys who have publicly commented on the litigation frequently cite this range as a reasonable projection. The lower end reflects a scenario where causation defenses hold up under Daubert scrutiny and bellwether juries are skeptical; the higher end reflects a scenario where juries consistently return large verdicts and Syngenta faces punitive damages exposure for alleged concealment of known risks.

Individual Case Value Estimates: $100,000 to $500,000

At the individual level, paraquat Parkinson's settlements are projected to range from approximately $100,000 to $500,000, with the specific value driven by factors that vary significantly from plaintiff to plaintiff. Understanding these factors helps claimants and their families develop realistic expectations.

Note: H&Y refers to the Hoehn and Yahr scale, the standard clinical staging system for Parkinson's disease. All ranges are attorney projections before contingency fees (typically 33–40%) and medical liens. No settlement has been finalized.

The factors that push a case toward the higher end of the range include: young age at diagnosis (meaning more years of disability and lost income), advanced disease severity, well-documented paraquat exposure with application logs and employment records, proximity evidence if the claimant lived near frequently sprayed fields, a credible lack of alternative causes (the defense will argue that other pesticides, genetics, or head injuries explain the Parkinson's), and high economic damages from lost wages in a skilled occupation or significant lifetime care costs. A former licensed pesticide applicator who developed early-onset Parkinson's at age 52, has extensive application records, and needs full-time care has a dramatically stronger case value than a claimant with only incidental exposure evidence and a diagnosis at age 78.

Farm Worker Demographics: Who Is Most Affected

The paraquat litigation disproportionately involves migrant and seasonal farm workers, a population that has faced profound inequalities in occupational health protection for decades. These workers often mixed, loaded, and sprayed paraquat without adequate protective equipment, frequently in hot weather when heat stress causes workers to remove gloves and masks. Spray drift exposure was common, and workers sometimes re-entered recently sprayed fields before waiting periods had elapsed.

Demographic data from agricultural employment studies suggests that a large share of the paraquat-exposed workforce consists of Hispanic and Latino workers, many of whom are immigrants. This population faces specific obstacles in the litigation: language barriers in understanding English-language warning labels, a history of legal vulnerability that may have discouraged reporting of health symptoms, and documentation gaps if they worked informally or for cash. Attorneys handling these cases have developed Spanish-language intake processes and work with community health organizations to identify affected workers who may not know that a lawsuit exists.

Other significantly affected groups include:

• Licensed pesticide applicators who mixed and applied paraquat as part of their regular job duties on commercial farms, golf courses, and utility corridors
• Farmers and farm owners who personally applied paraquat on their own operations before the restricted-use classification tightened applicator requirements
• Greenhouse and nursery workers who used paraquat for weed control in growing operations
• Residential neighbors of farms where paraquat was regularly applied, who were exposed through spray drift and contaminated water runoff
• Research scientists and toxicologists who handled paraquat in laboratory settings over extended periods

The geographic concentration of paraquat cases follows US agricultural patterns: California's Central Valley, the Midwest corn and soybean belt, the Southeast tobacco and cotton regions, and Texas agricultural areas are home to large numbers of affected workers. Some of the highest-exposure cases involve workers in states where paraquat was applied on multiple crops across multiple growing seasons for ten or more years.

Evidence Required to File a Paraquat Parkinson's Claim

Building a strong paraquat case requires two fundamental categories of evidence: proof of paraquat exposure and proof of a Parkinson's disease diagnosis. The intersection of those two elements — documented exposure that preceded the diagnosis — is the core of the legal case.

For exposure evidence, the strongest documentation includes:

• Pesticide application logs or spray records showing paraquat use, dates, and field locations
• Employment records, pay stubs, or W-2 forms from farm employers during the exposure period
• Pesticide applicator license records showing certification to apply restricted-use pesticides
• Purchase receipts or supplier records showing paraquat (Gramoxone or other brand names) was acquired
• Witness testimony from co-workers, supervisors, or family members about observed paraquat use
• Geographic records: if residential proximity exposure is alleged, maps, aerial photographs, or municipal records showing the claimant's address in relation to farms where paraquat was applied

For medical evidence, the required documentation includes:

• A formal Parkinson's disease diagnosis from a neurologist or movement disorder specialist, supported by clinical examination notes
• Brain imaging reports (MRI, DaT scan) supporting the diagnosis
• Medication records showing dopaminergic treatment consistent with Parkinson's
• A complete medical history addressing alternative causes such as prior head trauma, family history of Parkinson's, or other neurotoxic exposures

Attorneys typically retain a neurologist expert to provide a specific causation opinion linking the plaintiff's paraquat exposure to their Parkinson's diagnosis, and an industrial hygienist or toxicologist to quantify the exposure dose and evaluate its biological plausibility. These expert opinions are essential in mass tort litigation and represent a major cost borne by the plaintiffs' law firm on a contingency basis.

Paraquat's US Use Despite a 32-Country Ban

One of the most powerful facts in the paraquat litigation — and one that plaintiffs' attorneys use effectively before juries — is that paraquat has been banned in more than 32 countries while remaining legal for restricted commercial use in the United States. The European Union banned paraquat in 2007 after a scientific review concluded that no safe level of exposure could be established for human health. Countries that have prohibited or severely restricted paraquat include Switzerland (home of manufacturer Syngenta's headquarters), most of the EU member states, the United Kingdom, Brazil, and China.

The Swiss irony is a particular point of emphasis: Syngenta, headquartered in Basel, Switzerland, manufactures a chemical that has been illegal in its home country since 1989 — yet continues to sell it in the United States. Plaintiffs' attorneys argue this fact is powerful evidence that the defendants knew about paraquat's dangers long before American farm workers were warned, and that the US regulatory process was slower to act on the same scientific evidence that prompted bans elsewhere.

The EPA's continued registration of paraquat under the restricted-use framework has created a preemption defense used by the defendants: they argue that complying with EPA label requirements fulfills their legal duty to warn and preempts state tort claims. Courts have not uniformly accepted this federal preemption argument in the paraquat context, and it remains a live legal issue in the MDL. If preemption defenses succeed, they could significantly reduce the pool of recoverable damages; if they fail, the liability exposure for Syngenta and Chevron remains broad.

Social Security Disability for Parkinson's Disease

Many Parkinson's disease patients eventually become unable to work as the disease progresses, and Social Security Disability Insurance (SSDI) is a critical income replacement resource that can operate alongside a paraquat lawsuit settlement. The two programs are legally independent — receiving an SSDI award does not reduce your legal settlement, and a legal settlement does not eliminate your SSDI eligibility (though it may affect Supplemental Security Income, which is means-tested).

Parkinson's disease is specifically listed in the Social Security Administration's Blue Book neurological listings under Listing 11.06, which covers Parkinsonian syndrome with specific functional criteria. To meet the listing, the SSA requires documentation of significant rigidity, bradykinesia, or tremor in two extremities causing persistent disruption of motor function — criteria that most patients with moderate to advanced Parkinson's can satisfy with strong medical documentation from a movement disorder specialist.

For patients who do not meet the exact listing, SSDI may still be approved through a residual functional capacity (RFC) assessment showing that the combination of symptoms, medication side effects, and cognitive changes prevents the claimant from performing any work available in the national economy. Given that Parkinson's involves motor impairment, fatigue, speech difficulties, and in many patients significant cognitive decline, the functional case for SSDI is often compelling even in moderate-stage disease.

Use our free calculator to estimate your monthly SSDI benefit amount based on your work history and earnings record.

How Attorney Fees and Medical Liens Affect Your Net Recovery

Paraquat Parkinson's cases are handled by plaintiffs' attorneys on a contingency fee basis, meaning you owe no upfront payment and the attorney collects a percentage of your recovery only if your case settles or results in a verdict. Contingency fees in mass tort litigation typically range from 33% to 40% of the gross recovery, with some variation based on the law firm and the stage at which the case resolves.

In addition to attorney fees, claimants must account for medical liens. If Medicare, Medicaid, or a private health insurer paid for medical treatment related to your Parkinson's disease, those payors have a legal right to be reimbursed from your settlement proceeds. Medicare liens in particular are federally mandated and must be resolved before settlement funds are disbursed; failure to address them can expose the claimant to personal liability after settlement. The resolution process involves negotiating with Medicare's Secondary Payer program to reduce the lien to a fair amount, a process that experienced mass tort attorneys manage as a routine part of case resolution.

As a rough illustration: a moderate-stage Parkinson's plaintiff with a projected settlement value of $250,000 who pays a 33% contingency fee would net approximately $167,500 before any Medicare lien. If Medicare paid $40,000 in Parkinson's-related treatment costs and the lien is negotiated down to $20,000, the claimant's net recovery would be approximately $147,500. These are estimates only — every case has a different fee structure, lien amount, and negotiated reduction. Your attorney should provide a clear written breakdown of expected deductions before you sign a settlement release.

Estimate Your Paraquat Settlement Value

Frequently Asked Questions

How much can I get from a paraquat Parkinson's lawsuit settlement?

Individual paraquat Parkinson's settlements are projected to range from approximately $100,000 to $500,000 depending on Parkinson's disease severity (using the Hoehn and Yahr staging scale), the strength and duration of documented paraquat exposure, age at diagnosis, lost income, and ongoing care costs. Advanced-stage Parkinson's cases with long, well-documented occupational exposure histories are likely to settle at the higher end of that range. No global settlement has been finalized as of mid-2025, and these are attorney projections based on comparable MDL outcomes rather than confirmed settlement data.

Who qualifies for the paraquat Parkinson's lawsuit?

You may qualify if you have a confirmed Parkinson's disease diagnosis and a history of occupational or residential exposure to paraquat. Qualifying claimants most commonly include licensed pesticide applicators, farm workers who mixed or sprayed paraquat, agricultural employees at operations where Gramoxone or other paraquat products were used, and individuals who lived near fields where paraquat was regularly applied. You must be able to document both the exposure and the diagnosis. Attorneys typically offer a free case evaluation to determine whether your specific history meets the criteria used to accept cases into the MDL.

What is the current status of the paraquat MDL lawsuit in 2025?

The paraquat litigation is consolidated as MDL No. 3004 in the U.S. District Court for the Southern District of Illinois before Judge Nancy Rosenstengel. The MDL contained more than 5,000 cases as of late 2024 and continues to grow. Bellwether trials are scheduled in 2025. No global settlement with Syngenta or Chevron has been announced, but legal analysts expect settlement negotiations to accelerate after bellwether verdicts establish case valuations.

Is paraquat still legal in the United States?

Yes, paraquat remains legal for restricted commercial use in the United States, though it can only be purchased and applied by licensed commercial applicators. The US is a significant outlier: paraquat has been banned in the European Union since 2007 and is prohibited in more than 32 countries due to its extreme toxicity and established links to Parkinson's disease. The EPA's continued registration of paraquat under a restricted-use framework is itself a point of contention in the litigation, where plaintiffs argue that the regulatory gap between the US and the rest of the world reflects inadequate protection of farm workers.